Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina

Andrei A. Kramerov, Mehrnoosh Saghizadeh, Hao Pan, Andrea Kabosova, Mathias Montenarh, Khalil Ahmed, John S. Penn, Candy K. Chan, David R. Hinton, Maria B. Grant, Alexander V. Ljubimov

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.

Original languageEnglish (US)
Pages (from-to)1722-1736
Number of pages15
JournalAmerican Journal of Pathology
Volume168
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Casein Kinase II
Octreotide
Retina
Emodin
Retinal Neovascularization
Oxygen
Reverse Transcriptase Polymerase Chain Reaction
Astrocytes
Staining and Labeling
Retinopathy of Prematurity
Somatostatin
Rodentia
Endothelial Cells
Western Blotting
Immunohistochemistry
Messenger RNA
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Kramerov, A. A., Saghizadeh, M., Pan, H., Kabosova, A., Montenarh, M., Ahmed, K., ... Ljubimov, A. V. (2006). Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. American Journal of Pathology, 168(5), 1722-1736. https://doi.org/10.2353/ajpath.2006.050533

Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. / Kramerov, Andrei A.; Saghizadeh, Mehrnoosh; Pan, Hao; Kabosova, Andrea; Montenarh, Mathias; Ahmed, Khalil; Penn, John S.; Chan, Candy K.; Hinton, David R.; Grant, Maria B.; Ljubimov, Alexander V.

In: American Journal of Pathology, Vol. 168, No. 5, 05.2006, p. 1722-1736.

Research output: Contribution to journalArticle

Kramerov, AA, Saghizadeh, M, Pan, H, Kabosova, A, Montenarh, M, Ahmed, K, Penn, JS, Chan, CK, Hinton, DR, Grant, MB & Ljubimov, AV 2006, 'Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina', American Journal of Pathology, vol. 168, no. 5, pp. 1722-1736. https://doi.org/10.2353/ajpath.2006.050533
Kramerov, Andrei A. ; Saghizadeh, Mehrnoosh ; Pan, Hao ; Kabosova, Andrea ; Montenarh, Mathias ; Ahmed, Khalil ; Penn, John S. ; Chan, Candy K. ; Hinton, David R. ; Grant, Maria B. ; Ljubimov, Alexander V. / Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. In: American Journal of Pathology. 2006 ; Vol. 168, No. 5. pp. 1722-1736.
@article{064276ac73714329a0486ed4b435c5c1,
title = "Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina",
abstract = "We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.",
author = "Kramerov, {Andrei A.} and Mehrnoosh Saghizadeh and Hao Pan and Andrea Kabosova and Mathias Montenarh and Khalil Ahmed and Penn, {John S.} and Chan, {Candy K.} and Hinton, {David R.} and Grant, {Maria B.} and Ljubimov, {Alexander V.}",
year = "2006",
month = "5",
doi = "10.2353/ajpath.2006.050533",
language = "English (US)",
volume = "168",
pages = "1722--1736",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina

AU - Kramerov, Andrei A.

AU - Saghizadeh, Mehrnoosh

AU - Pan, Hao

AU - Kabosova, Andrea

AU - Montenarh, Mathias

AU - Ahmed, Khalil

AU - Penn, John S.

AU - Chan, Candy K.

AU - Hinton, David R.

AU - Grant, Maria B.

AU - Ljubimov, Alexander V.

PY - 2006/5

Y1 - 2006/5

N2 - We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.

AB - We previously documented protein kinase CK2 involvement in retinal neovascularization. Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopathy (OIR). CK2 expression in human and rodent retinas with and without retinopathy and in astrocytic and endothelial cultures was examined by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction. A combination of CK2 inhibitors, emodin or 4,5,6,7-tetrabromo-benzotriazole, with octreotide was injected intraperitoneally from postnatal (P) day P11 to P17 to block mouse OIR. All CK2 subunits (α, α′, β) were expressed in retina, and a novel CK2α splice variant was detected by reverse transcriptase-polymerase chain reaction. CK2 antibodies primarily reacted with retinal astrocytes, and staining was increased around new intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels were negative. Cultured astrocytes showed increased perinuclear CK2 staining compared to endothelial cells. In the OIR model, CK2 mRNA expression increased modestly on P13 but not on P17. Octreotide combined with emodin or 4,5,6,7-tetrabromobenzotriazole blocked mouse retinal neovascularization more efficiently than either compound alone. Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies.

UR - http://www.scopus.com/inward/record.url?scp=33646508546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646508546&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2006.050533

DO - 10.2353/ajpath.2006.050533

M3 - Article

VL - 168

SP - 1722

EP - 1736

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -